Saline recall issued after potassium chloride bag found inside

Otsuka ICU Medical LLC has issued a voluntary nationwide recall of one lot of 0.9% sodium chloride injection, USP, 100 mL, after discovering that some units may actually contain 10 mEq potassium chloride injection inside saline-labeled overwrap. FDA posted the company’s announcement on September 21, 2026, four days after the company’s September 17 notice. The recalled product is lot 1042188, NDC 0990-7984-23, expiration date October 31, 2027. (fda.gov)

The immediate trigger was a customer complaint. According to the FDA-posted recall notice, a highly concentrated 100 mL potassium chloride bag, lot 1035181, NDC 0990-7074-26, was found inside overwrap labeled as 0.9% sodium chloride. Otsuka ICU Medical said the affected saline lot was manufactured on November 13, 2025, and distributed across the U.S. between December 30, 2025, and June 22, 2026. As of the announcement, the company said it had not received reports of adverse events tied to the recall. (fda.gov)

This lands in a market where IV fluid reliability is already under close watch. Otsuka ICU Medical is a relatively new joint venture, completed in May 2025, between ICU Medical and Otsuka Pharmaceutical Factory. The companies said the venture was designed to strengthen North American IV solutions supply resiliency and innovation, combining ICU Medical’s Austin, Texas, production footprint with Otsuka’s broader IV manufacturing network. That background matters because the recall touches a product category that many veterinary hospitals depend on every day and that has faced repeated supply and quality disruptions in recent years. (ir.icumed.com)

The clinical risk here is straightforward and serious. FDA’s posted notice says there is a reasonable probability that inadvertent injection of the concentrated potassium chloride product could lead to adverse events and potentially fatal outcomes. The company specifically warned of neuromuscular dysfunction, muscle weakness, ascending paralysis, vertigo, mental confusion, hypotension, cardiac dysrhythmias, and death from cardiac arrest, with especially high risk in patients with renal impairment, prior arrhythmias, or other factors that increase vulnerability to hyperkalemia. (fda.gov)

While the recall is framed for human healthcare, veterinary relevance is real. AVMA has previously amplified ICU Medical potassium chloride recall notices specifically because those products may be used in veterinary settings, underscoring that human-labeled injectable recalls can cross directly into animal practice workflows. In day-to-day veterinary medicine, saline bags may be used for fluid therapy, catheter maintenance, dilution, and emergency care, so a packaging mix-up at the overwrap level creates risk at the point of selection, especially in busy treatment areas where clinicians may reasonably trust the outer label. (avma.org)

There was limited outside expert commentary available at the time of writing, but the broader industry reaction has been to treat this as another reminder that injectable product verification can’t stop at shelf pick. The Oncology Nursing Society flagged the recall for clinicians within days of the FDA posting, and its safety roundup placed it alongside several other September 2026 injectable-drug and IV-fluid recalls, including separate sodium chloride recalls tied to particulate matter. That context suggests this event may reinforce calls for tighter receiving checks, barcode verification, and staff education around inspecting both overwrap and inner bag labeling before use. That last point is partly an inference from the pattern of recent recalls and the nature of this packaging error. (ons.org)

Why it matters: For veterinary professionals, this is less about one manufacturer’s problem than about process vulnerability. Many clinics and hospitals buy from human medical supply channels, and saline is so familiar that it can become a low-scrutiny item compared with controlled drugs or chemotherapy agents. A recall involving potassium chloride hidden inside saline packaging is a reminder to review how recalled lots are identified, how incoming fluids are checked, and whether technicians and doctors are empowered to pause administration when packaging looks inconsistent. It also raises a practical inventory question: whether affected product may still be sitting in satellite storage, crash carts, ambulatory vehicles, or referral-hospital treatment areas months after distribution. (fda.gov)

What to watch: The next steps are likely to include ongoing customer returns, possible FDA recall classification, and any manufacturer updates on root cause or corrective actions. Veterinary teams should also watch whether this recall feeds into broader conversations about IV fluid safety and supply resilience, especially since multiple saline-related recalls were posted by FDA in August and September 2026. (fda.gov)